Additionally, Liang et al., (2011) demonstrated that high grade and stage breast cancer tissues (HER2+ and triple negative groups) express higher levels of LAT1. Here we identified relatively high expression of LAT1 in all subtypes and particularly higher expression in the negative HER2 groups that are usually more difficult to treat. This evidence concerns the gene SLC7A5 and breast carcinoma.